CERA

Science and Research

MYLIGHT: A 52-week Multicenter, Randomized, Double-Masked, 2-Arm Parallel Study To Compare Efficacy, Safety And Immunogenicity Of SOK583A1 To Eylea®, Administered Intravitreally, In Patients With Neovascular Age-Related Macular Degeneration

This study assesses the efficacy, safety and immunogenicity of SOK583A1 versus Eylea® in patients with neovascular age-related macular degeneration (AMD).

Overview

To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.

The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.